



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61F 13/00, A61K 9/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/17215</b> <b>(43) International Publication Date:</b> 30 April 1998 (30.04.98)
<b>(21) International Application Number:</b> PCT/US97/19198 <b>(22) International Filing Date:</b> 22 October 1997 (22.10.97) <b>(30) Priority Data:</b> 60/029,268                      24 October 1996 (24.10.96)                      US <b>(71) Applicant:</b> SHERWOOD MEDICAL COMPANY [US/US]; 1915 Olive Street, St. Louis, MO 63103-1642 (US). <b>(72) Inventor:</b> HUANG, Yeong, Hua; 2163 Palestra Drive #11, St. Louis, MO 63146 (US). <b>(74) Agents:</b> SMITH, Montgomery, W.; Sherwood Medical Com- pany, 1915 Olive Street, St. Louis, MO 63103-1642 (US) et al.		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, MI, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
<b>(54) Title:</b> HYDROGEL WOUND DRESSING AND THE METHOD OF MAKING AND USING THE SAME		
<b>(57) Abstract</b>  A hydrogel wound dressing which is highly absorptive, contours to a wound site and maintains the wound in a moist state to promote healing thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Licchtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HYDROGEL WOUND DRESSING AND THE METHOD  
OF MAKING AND USING THE SAME

Technical Field

The present invention relates to a hydrogel wound  
5 dressing and a method of making and using the same. More  
particularly, the present invention relates to a flexible  
hydrogel wound dressing which is highly absorptive, contours  
to a wound site and maintains the wound in a moist state to  
promote healing thereof and the method of producing and  
10 using the same.

Background Art

The treatment of draining wounds is a problem in the  
medical profession. Wound exudate such as blood, serum and  
purulent matter from a draining wound can lead to bacterial  
15 growth and delayed healing if not treated properly. Often  
times it is difficult to maintain wounds free of such wound  
secretions to allow for healing. Another concern in treating  
such draining wounds is that some believe that allowing a  
wound to heal in a slightly moist state may actually  
20 accelerate healing. Accordingly, the medical profession  
desires a means for maintaining draining wounds in a clean,  
moist protected state.

Currently in an attempt to meet such wound treatment  
needs there are wound exudate absorption compositions which  
25 are comprised of hydrogel materials in powder form. One  
example of such a powder material includes dextranomer  
beads. Dextranomer beads are hydrophilic spherical beads  
which are applied to a wound to absorb wound exudate.

Disadvantages noted in using materials in powder form include difficulty in even application, lumping and clumping of the material after application and difficulty in removal of the material from the wound site without damaging the  
5 newly formed tissues of the wound.

U.S. Patent No. 4,226,232 discloses the blending of a hydrogel material with a liquid curing agent such as polyethylene glycol prior to introducing the material to the wound. A difficulty of using this material is that it can  
10 not be sterilized by irradiation due to the formation of free radicals within the gel material. The free radicals within the gel material cause instability of the product and thereby shortens the shelf life thereof.

U.S. Patent No. 5,059,424 discloses a wound dressing  
15 comprising a backing member with an adhesive layer and hydrogel material of 15-30% polyhydric alcohol, 8-14% isophorone diisocyanate prepolymer, 5-10% polyethylene oxide-based diamine, 0-1% salt and the balance water. Difficulties associated with the use of this wound product includes the  
20 limitation of not being able to cut the dressing to a size appropriate for the particular wound and still have the backer intact. Additionally, the hydrogel material disclosed in this patent lacks the necessary strength to be used and removed, without the added support of the backer material.

25 The need exists for a sterile wound dressing which provides a size appropriate protective covering for a draining wound capable of absorbing exudate from the wound. It is also desirable to have a wound dressing suitable to protect a wound from debris and foreign matter capable of

contaminating the wound. It is also desirable to have a wound dressing which cushions the wound from pressure. It is also desirable to have a wound dressing which does not adhere to the new tissue forming in the wound. It is also  
5 desirable to have a wound dressing which maintains a wound in a slightly moist state to promote healing.

#### Disclosure of Invention

The present invention relates to a hydrogel wound dressing capable of absorbing exudate from a draining wound  
10 without becoming adhered thereto. The wound dressing maintains the wound in a slightly moist state to promote healing of the wound while retaining its overall strength to allow for removal thereof in a unitary fashion.

The hydrogel wound dressing of the present invention is  
15 a polyurethane hydrogel material comprising polyurethane prepolymer, deionized water, glycols and optionally an antimicrobial and/or a bacteriostatic agent.




The method of producing the hydrogel material of the present invention involves hydrolysis and addition reactions  
20 to produce a three-dimensional cross-linked polyurethane hydrogel as described in more detail below. The resultant polyurethane hydrogel material is blended and cast molded to allow for gelation thereof in less than 180 minutes at room temperature. The subject wound dressing is then optionally  
25 subjected to temperatures below 0° C. to remove excess water and then packaged and sterilized using radiation sterilization or other suitable sterilization technique, prior to distribution.

Best Mode(s) for Carrying Out the Invention

The polyurethane hydrogel wound dressing of the present invention is capable of absorbing moisture from a wound site until the overall composition comprises approximately 95

5 percent to 99 percent water or fluid. The subject non-adhesive hydrogel dressing provides for moist wound healing, absorbs wound exudate, allows for fewer dressing changes, allows for easy removal with no trauma to the wound, protects the wound from contamination and minimizes odor.

10 The polyurethane hydrogel material of the present invention is generally produced through a hydrolysis and an addition reaction. The hydrolysis and addition reactions are achieved by blending polyurethane prepolymer with polypropylene glycol, water and propylene glycol in  
15 accordance with the following reactions:

**STEP 1:****STEP 2:****STEP 3:**

wherein the R<sup>1</sup> groups may be the same or different selected from the group consisting of C<sub>1-12</sub> alkyl repeating groups such as for example methyl, ethyl or propyl but preferably propyl to increase clarity; C<sub>1-12</sub> mono or poly hydroxyalkyl repeating groups such as for example hydroxymethyl, or dihydroxypropyl but preferably dihydroxypropyl to increase clarity; C<sub>1-12</sub> acyl repeating groups such as for example acetyl or proprionyl but preferably proprionyl to increase clarity; C<sub>1-12</sub> alkoxyalkyl repeating groups such as for example methoxyethyl or ethoxypropyl but preferably ethoxypropyl to increase clarity; C<sub>1-12</sub> aminoalkyl repeating groups such as for example aminomethyl or aminopropyl but preferably aminopropyl to increase clarity; C<sub>1-12</sub> acylaminoalkyl repeating groups such as for example acetylaminomethyl or proprionylaminomethyl but preferably prorionylaminomethyl to increase clarity; C<sub>1-12</sub> oxyalkyl repeating groups such as but not limited to oxyethylene, oxypropylene or oxybutylene but preferably oxyethylene and/or oxypropylene to increase clarity, such repeating units having an average molecular weight of about 7,000 to about 30,000 capped with aromatic, aliphatic or cycloaliphatic isocyanates, diisocyanates or polyisocyanates, but most preferably diisocyanate- or polyisocyanate-capped repeating units as described above having molecular weights of at least 10,000. The use of aliphatic polyisocyanates is preferred in the present invention to achieve a greater degree of handling freedom since aliphatic isocyanate-capped prepolymers typically require longer periods of time to gel. In addition,

aliphatic polyisocyanates will be preferred when the material is intended to be used in medical applications, because of decreased toxicological considerations. By contrast, prepolymers capped with aromatic polyisocyanates will gel in about 30 to 60 seconds as opposed to 20 to 90 minutes as typical for the aliphatic isocyanates. Gelation within 30 to 60 seconds is a disadvantage for use in the present application due to the lack of adequate time for proper blending of the materials and molding thereof. The subject reaction mixture gels in approximately 15 to 180 minutes at room temperature but preferably approximately 30 to 90 minutes.


Examples of suitable difunctional and polyfunctional isocyanates include but are not limited to isophorone diisocyanate, toluene-2,4-diisocyanate, toluene-2,6-diisocyanate, mixtures of toluene-2,4, and 2,6-diisocyanate, ethylene diisocyanate, ethylidene diisocyanate, propylene-1,2-diisocyanate, cyclohexylene-1,2-diisocyanate, cyclohexylene-1,4-diisocyanate, m-phenylene diisocyanate, 3,3'-diphenyl-4,4'-biphenylene diisocyanate, 4,4'-biphenylene diisocyanate, 4,4'-diphenylmethane diisocyanate, 3,3'-dichloro-4,4'-biphenylene diisocyanate, 1,6-hexamethylene diisocyanate, 1,4-tetramethylene diisocyanate, 1,10-decamethylene diisocyanate, cumene-2,4-diisocyanate, 1,5-naphthalene diisocyanate, methylene dicyclohexyl diisocyanate, 1,4-cyclohexylene diisocyanate, p-tetramethylxylylene diisocyanate, p-phenylene diisocyanate, 4-methoxy-1,3-phenylene diisocyanate, 4-chloro-1,3-phenylene diisocyanate, 4-bromo-1,3-phenylene diisocyanate, 4-ethoxy-



- 1,3-phenylene diisocyanate, 2,4-dimethylene-1,3-phenylene diisocyanate, 5,6-dimethyl-1,3-phenylene diisocyanate, 2,4-diisocyanatodiphenylether, 4,4'-diisocyanatodiphenylether, benzidine diisocyanate, 4,6-dimethyl-1,3-phenylene
- 5 diisocyanate, 9,10-anthracene diisocyanate, 4,4'-diisocyanatodibenzyl, 3,3'-dimethyl-4,4'-diisocyanatodiphenylmethane, 2,6-dimethyl-4,4'-diisocyanatodiphenyl, 2,4-diisocyanatostilbene, 3,3'-dimethoxy-4,4'-diisocyanatodiphenyl, 1,4-
- 10 anthracenediisocyanate, 2,5-fluorenediisocyanate, 1,8-naphthalene diisocyanate, 2,6-diisocyanatobenzfuran, 2,4,6-toluene triisocyanate, p,p',p"-triphenylmethane triisocyanate, trifunctional trimer of isophorone diisocyanate, trifunctional biuret of
- 15 hexamethylenediisocyanate, trifunctional trimer of hexamethylene diisocyanate and polymeric 4,4'-diphenylmethane diisocyanate, preferably diisophorone diisocyanate or isophorone diisocyanate for a preferred rate or gelation.
- 20  $R^2OH$  is selected from the group consisting of  $C_{1-12}$  monohydric alcohols such as ethanol, methanol or propanol wherein propanol is preferred to increase clarity,  $C_{1-12}$  diols such as glycols and derivatives thereof wherein propylene glycol is preferred to increase clarity, and  $C_{1-12}$
- 25 polyalkyldiols such as polypropylene glycol, polyethylene glycol or polybutylene glycol wherein polypropylene glycol is preferred to increase clarity. Most preferably, propylene glycol and/or polypropylene glycol is used to improve clarity or transparency of the final product. Additionally,

R<sup>2</sup> represents the corresponding C<sub>1-12</sub> alkyl group C<sub>1-12</sub> hydroxyalkyl group, or C<sub>1-12</sub> polyhydroxyalkyl group derived from R<sup>2</sup>OH. A clear or transparent product allows for undisturbed viewing of the wound for better wound care management.

The above noted chemical reactions illustrate the process by which the subject hydrogel is produced. In the initial step, as illustrated in STEP 1, a polyurethane prepolymer such as a isophorone diisocyanate prepolymer but preferably a prepolymer of the following chemical composition



wherein the R<sup>3</sup> groups may be the same or different selected from the group consisting of hydrogen, and C<sub>1-10</sub> alkyl such as for example methyl or ethyl but preferably methyl; and n represents integers which may differ from one another within the range of 1 to 200. A mixture of hydrogen and methyl groups are the preferred R<sup>3</sup> groups for the above-described prepolymer in order to increase the flexibility and hydrophilicity of the final product. The prepolymer is reacted with a C<sub>1-12</sub> alcohol, C<sub>1-12</sub> diol, C<sub>1-12</sub> alkyldiol and/or C<sub>1-12</sub> polyalkyldiol as described above, such as polypropylene glycol or propylene glycol in an alcoholysis reaction to

form a polyurethane. Next, as illustrated in STEP 2 unreacted prepolymer further reacts with water to undergo a hydrolysis reaction to form a polyamine and carbon dioxide. Due to the fact that the polyamine produced in STEP 2 is an unstable intermediate in this reaction process, STEP 3 illustrates the continued reaction of the polyamine of STEP 2, undergoing an addition reaction to form a stable polyurea. This series of reactions rather than producing a foam, results in a three-dimensional cross-linked polyurethane/polyurea hydrogel. It is important to note that the water is added at the end of the second step of the procedure in order to prevent premature gelling and foaming. Additionally, the percentage free of isocyanate present in the prepolymer directly affects the gelation reaction rate. For this reason, in the present invention the percentage of free isocyanate present in the reaction mixture is strictly controlled to a level below 5 percent to slow the reaction. Another consideration to be noted is that the faster the reaction rate, the faster the carbon dioxide gas is produced, which if not properly controlled causes the formation of a foam rather than a hydrogel. It is the control of these critical factors, i.e., the percentage of isocyanate present and the reaction rate, among the other considerations noted herein, which allows one to produce the unexpectedly superior hydrogel of the present invention.

In order for one to achieve the desired reaction mixture of the present invention and form a hydrogel of desirable strength and integrity for the intended use, STEP 1 involves blending together approximately 25 to 70 percent

of the polyurethane prepolymer but preferably approximately 34.9 percent and approximately 30 to 75 percent of a polyalkyl diol such as polypropylene glycol but preferably approximately 65.1 percent to produce Product A. STEP 2

5 involves combining approximately 50 to 90 percent deionized water but most preferably approximately 76 percent, approximately 5-15 percent of an alkyl diol such as propylene glycol but preferably about 9.5 percent, and approximately 0 to 40 percent of a polyalkyl diol such as

10 polypropylene glycol but preferably about 14.5 percent to produce Product B to react with Product A. Approximately 15 to 60 percent of Product A but preferably about 43.7 percent is blended with approximately 40 to 85 percent of Product B but preferably about 56.3 percent to produce the desired

15 hydrogel wound dressing of the present invention. Optionally, 0-5% but preferably 1-3% of a antimicrobial or a bacteriostatic agent can be added to the final reaction mixture or Product B. Suitable such antimicrobial and bacteriostatic agents include bismuth tribromophenate,

20 bacitracin, erythromycin, silver sulfadiazine, idoxuridine, triflurouddine, vidarabine, pyrimethamine. Preferably bismuth tribromophenate or silver sulfadiazine are optionally added to the reaction mixture to decrease the risk of infection and odor. The resultant hydrogel wound

25 dressing is characterized in that it comprises 5 to 20 percent by weight of a polyurethane prepolymer, 3 to 45 percent by weight of polypropylene glycols an propylene glycols and the balance water and optional additives.

The polyurethane hydrogel of the present invention is manufactured as further described in the following examples:

**Example A: Hydrogel Produced From Isophorone Diisocyanate based Prepolymer**

5 Three grams of isophorone diisocyanate prepolymer was mixed thoroughly first with 5.6 grams of polypropylene glycol (Portion A). Then 8.4 grams of deionized water was mixed with 1.05 grams of propylene glycol and 1.6 grams of polypropylene glycol (Portion B). Portion A and Portion B  
10 were mixed thoroughly with a stirring rod for about two to 5 minutes until a homogeneous solution was formed. The solution was then cast into a 4"x4" mold and maintained undisturbed for 90 minutes at room temperature while the gelling reaction occurred. The mold was kept in a closed  
15 container at room temperature overnight to prevent water evaporation and to permit essentially complete chemical reaction of all isocyanate end groups. The final hydrogel upon removal from the mold was flexible, transparent and able to absorb water four times, i.e., 400 percent, its own  
20 weight.

**Example B: Hydrogel Produced from Toluene Diisocyanate based Prepolymer**

Five grams of propylene glycol was mixed with five grams of toluene diisocyanate prepolymer (Portion A). Then fifteen  
25 grams of deionized water was mixed with seven grams of

propylene glycol (Portion B). Portion A and Portion B were quickly mixed and cast into two aluminum weighing dishes. The material gelled within 30 minutes. Both dishes filled with the gelled material were kept in a closed container at room temperature overnight to prevent water evaporation and to permit essentially complete chemical reaction of all isocyanate end groups. The final hydrogel material upon removal from the dishes was flexible, transparent and able to absorb water four times, i.e., 400 percent, its own weight.

**Example C: Hydrogel Produced with bacteriostatic agent Bismuth Tribromophenate (BTP)**

The hydrogel with BTP was formed by repeating the preparation of Example A, except 0.6 grams of BTP was added to Portion B. The final hydrogel was flexible and able to absorb water two and a half times, i.e., 250 percent, its own weight.

**Example D: Hydrogel Produced with antimicrobial Silver Sulfadiazine (SSD)**

The hydrogel with SSD was formed by repeating the preparation of Example A, except 0.2 grams of SSD was added to Portion B. The final gel was flexible and able to absorb water three times i.e., 300 percent, its weight.

Once the hydrogel is blended as described in detail in the above Examples, the gel may be cast and molded in any size or shape but is preferably molded into ropes having a length ranging from about two to twelve inches but  
5 preferably between four to eight inches and a width ranging from 0.1 to 2 inches but preferably about 0.25 to 0.75 inches or into disks having a diameter ranging between one and twelve inches but most preferably between two and six inches for ease of use. The thickness of the disks and ropes  
10 may vary substantially from .01 to 1 inch in thickness but most preferably are molded to .1 inch to .5 inch in thickness for ease of use with acceptable absorption.

The unexpected significant advantages of the present hydrogel dressing achieved through the particular reaction  
15 ratios noted above include increased absorption capabilities and increased strength. The increased strength of the subject hydrogel material eliminates the need for backing material as described in the prior art. Additionally, the hydrogel is stable, does not become brittle or crack with  
20 moisture loss, and has an extended shelf-life over other such materials.

The subject hydrogel dressing so produced is clear unless altered by additives such as bacteriostatic agents and the like. After the hydrogel is cast, molded, and  
25 formed, which usually takes approximately one and one half hours at room temperature. The gelling time can be shortened by curing the hydrogel at a higher temperature. The hydrogel once formed may be exposed to low temperatures such as below 0° C for approximately one half to four hours but preferably

approximately one to two hours to extract excess water used to fully complete the reactions as described above. This extraction of excess moisture significantly and unexpectedly increases the absorptive capabilities of the subject wound dressing which is capable of absorbing approximately 2 to 6 times its weight.

The subject hydrogel dressing is packaged and sterilized using an appropriate sterilization technique or may be sterilized and then packaged using aseptic technique. Appropriate methods of sterilization and packaging are known to those skilled in the art and include gamma radiation, electronic beam, ethylene oxide and like methods. Preferably, the subject hydrogel wound dressing is packaged and then sterilized using gamma radiation by cobalt 60 with 1 to 3 mrads but preferably 2 mrads in two independent exposure cycles.

Appropriate packaging for the subject hydrogel wound dressing includes metallic foil pouches such as aluminum foil pouches, polyethylene film, ethylene vinyl acetate film, polypropylene film, polyvinyl chloride film, and like packages known to those skilled in the art but preferably an ethylene vinyl acetate film liner with an aluminum foil pouch as an outer package to maintain moisture level.

The method of using the subject hydrogel wound dressing includes removing the dressing from its packaging and placing the dressing on or in the wound. Depending on the amount of exudate draining from the wound site, the dressing should be changed approximately every 1 to 2 days. The dressing in rope form can also be used for deep tunnel



wounds. The dressing may be cut using aseptic technique to a size appropriate for a particular wound before placing the dressing on the wound.

5 If after cutting the subject wound dressing the unused portion experiences water loss, the same may be rehydrated using aseptic technique and sterilized water.

It is seen therefore that the present hydrogel wound dressing provides an effective moist wound dressing to maintain draining wounds in a clean protected state. The  
10 wound dressing and method of making and using the same disclosed herein has specific advantages over the heretofore known means of treating draining wounds. The subject wound dressing eliminates risks associated with the treatment of draining wounds, lessens tissue damage upon removal thereof  
15 and may be cut to the appropriate size for ease of placement and use. Hence, for these reasons as well as others, some of which hereinabove set forth, it is seen that the present hydrogel wound dressing represents a significant advancement in the art which has substantial commercial significance.

20 While there is shown and described herein certain specific embodiments of the invention, it will be manifest to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not  
25 limited to the particular forms herein shown and described except insofar as indicated by the scope of the appended claims.

Claims

1. A hydrogel wound dressing comprising from 5 to 20 percent by weight of a polyurethane prepolymer, from 3 to 45 percent by weight of polypropylene glycols and propylene glycols, and the balance water.

2. The hydrogel wound dressing of claim 1 wherein a bacteriostatic agent has been added to reduce wound odor and risk of infection.

3. The hydrogel wound dressing of claim 1 wherein a bacteriostatic agent selected from the group consisting of bismuth tribromophenate, bacitracin and erythromycin has been added to reduce wound odor and risk of infection.

4. The hydrogel wound dressing of claim 1 wherein bismuth tribromophenate has been added to reduce wound odor and risk of infection.

5. The hydrogel wound dressing of claim 1 wherein an antimicrobial agent has been added to reduce wound odor and risk of infection.

6. The hydrogel wound dressing of claim 1 wherein an antimicrobial agent selected from the group consisting of silver sulfadiazine, idoxuridine, trifluorouddine, vidarabine and pyrimethamine has been added to reduce wound odor and risk of infection.

7. The hydrogel wound dressing of claim 1 wherein silver sulfadiazine has been added to reduce wound odor and risk of infection.

8. The hydrogel wound dressing of claim 1 wherein said  
5 dressing is approximately 0.01 to 1.00 inch in thickness.

9. The hydrogel wound dressing of claim 1 wherein said dressing is formed in the shape of a disc with a diameter ranging from approximately 1.0 inches to 12.0 inches.

10. The hydrogel wound dressing of claim 1 wherein said  
10 dressing is formed in the shape of a rope with length ranging from approximately 2 inches to 12 inches and width from 0.10 to 2.00 inches.

11. The hydrogel wound dressing of claim 1 wherein said dressing is capable of absorbing approximately 2 to 6 times  
15 its weight.

12. A method of producing a hydrogel wound dressing comprising:

forming a first solution of polyurethane prepolymer and  
20 polypropylene glycol;

forming a second solution of water, propylene glycol and polypropylene glycol; and

combining said first solution with said second solution.

13. The method of claim 12 wherein 15 to 60 percent of said first solution is combined with 40 to 85 percent of said second solution.

14. The method of claim 12 wherein 43.7% of said first  
5 solution is combined with 56.3% of said second solution.

15. The method of claim 12 wherein said second solution includes a bacteriostatic agent.

16. The method of claim 12 wherein said second solution includes a bacteriostatic agent selected from the group  
10 consisting of bismuth tribromophenate, bacitracin and erythromycin.

17. The method of claim 12 wherein said second solution includes bismuth tribromophenate.

18. The method of claim 12 wherein said second solution  
15 includes approximately 5 percent by weight bismuth tribromophenate.

19. The method of claim 12 wherein said second solution includes an antimicrobial agent.

20. The method of claim 12 wherein said second solution  
20 includes a bacteriostatic agent selected from the group consisting of silver sulfadiazine, idoxuridine, trifluorouddine, vidarabine and pyrimethamine.

21. The method of claim 12 wherein said second solution includes silver sulfadiazine.

22. The method of claim 12 wherein said second solution includes approximately 2 percent by weight silver  
5 sulfadiazine.

23. A method of using the hydrogel wound dressing produced in claim 12 comprising sterilizing said hydrogel dressing and placing said hydrogel dressing on or in a wound.

10 24. The method of claim 12 wherein said combined first and second solutions are cast and molded.

25. The method of claim 12 wherein said combined first and second solutions are cast and molded to form a dressing approximately 0.01 inch 1.0 inch thick.  
15

26. The method of claim 12 wherein said combined first and second solutions are cast and molded to form a dressing in the shape of a disc with a diameter ranging from approximately 1.0 inches to 12.0 inches.

20 27. The method of claim 12 wherein said combined first and second solutions are cast and molded in the shape of a rope with approximately 2 to 12 inches in length and 0.1 to 2.0 inches in width.

28. The method of claim 12 wherein said combined first and second solutions gel in approximately 30 minutes to 120 minutes at room temperature.

29. The method of claim 12 wherein said combined first  
5 and second solutions after gelled are exposed to a low temperature for approximately one half to four hours.

30. The method of claim 12 wherein said combined first and second solutions after gelled are exposed to a low temperature of approximately 0° C for approximately one half  
10 to four hours.

31. The method of claim 12 wherein said combined first and second solutions gel to form a hydrogel which may be sterilized.

15 32. The method of claim 12 wherein said combined first and second solutions gel to form a hydrogel which is sterilized by gamma radiation.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/19198

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 424/443

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/443

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,401,651 A (KNUTSON) 30 August 1983, col. 1, lines 15-17,39-41; col. 5, lines 32-33 ; col. 16, lines 18-19.	1-5 ,16-19
A	US 5,300,291 A (SABLOTSKY) 05 April 1994, col. 4, lines 45-48; col. 7, lines 9-68.	6-15,20-32

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 JANUARY 1998

Date of mailing of the international search report

23 FEB 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

WILLIAM E. BENSTON, JR.

Telephone No. (703) 308-2351

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US97/19198

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

A61F 13/00; A61K 9/70